EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Takeover
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita
28.07.2021 / 07:00
Acquisition Expands Scope of Development of Inhaled Formulation of Aviptadil
Geneva, Switzerland, July 28, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (
Relief ), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that it has closed a definitive agreement to acquire all outstanding shares of AdVita Lifescience GmbH (
AdVita ), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases.
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Relief Therapeutics Holding AG (via Public) / Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Search jobs 17-May-2021 Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study
17.05.2021 / 07:00
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
Geneva, Switzerland, May 17, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)(
Relief ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury, is pleased to see the recent announcement by APR Applied Pharma Research S.A. (
APR ) regarding the initiation of a pivotal clinical trial with its novel nasal spray, temporarily codenamed APR-AOS2020, a Class III medical device, in patients with mild COVID-19. The trial is designed to evaluate the efficacy and safety of the product in reducing vir